A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Starting soon · Phase 2
Conditions studied: Cardiac Sarcoidosis
In brief
The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is: \- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT? Participants will: * Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks * Visit the clinic every two to four weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib
Key facts
- Study ID
- NCT06868381
- Run by
- Stanford University
- People needed
- 10
- Starts
- 2026-04-01
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-02-10
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University — Palo Alto, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.